[Cancer breakthrough pain. Indications for rapidly effective opioids].

Area of Science:

• Oncology
• Pharmacology
• Pain Management

Context:

• Tumor pain pharmacotherapy involves managing both baseline pain and breakthrough pain.
• Current treatments for breakthrough pain may not always align with its rapid onset and intensity.
• Oral opioid formulations can have limitations in addressing the immediate needs of breakthrough pain.

Purpose:

• To evaluate the role of rapidly effective opioids in managing tumor breakthrough pain.
• To highlight the limitations of existing non-retarded oral opioids for breakthrough pain.
• To introduce transmucosal fentanyl preparations as a new alternative.

Summary:

• Tumor pain management necessitates sustained basic analgesia and rapid intervention for breakthrough pain.
• Breakthrough pain, defined by sudden onset and rapid escalation, requires equally swift-acting analgesics.
• Five novel, rapidly effective transmucosal fentanyl formulations are now available, addressing the unmet needs in breakthrough pain treatment.

Impact:

• Improved patient outcomes through more effective management of severe breakthrough pain episodes.
• Enhanced quality of life for cancer patients experiencing unpredictable pain flares.
• Expanded therapeutic options for oncologists and pain specialists in treating complex cancer pain.